RecruitingNCT06981663
Effects of Fibres Combined With Probiotics on Uric Acid in an ex Vivo Fermentation Model
Potential Effects of Fibres Combined With Probiotics on Uric Acid and Related Metabolites in an ex Vivo Fermentation Model
Sponsor
Örebro University, Sweden
Enrollment
15 participants
Start Date
Jun 12, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
In this study, we will collect faecal samples from individuals with hyperuricaemia (assessed by blood test) and perform in vitro faecal fermentation studies to assess how probiotics in combination with fibres affect urate metabolism in these faecal samples.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria6
- Signed informed consent prior to any study-related procedures
- Age 18-80 years old
- BMI range 18.5-35 kg/m2
- Blood uric acid above 0.36 mmol/L (6 mg/dl)
- Willing to abstain from regular consumption of probiotic supplements or food products containing probiotic bacteria (including fermented food and beverages), until collection of faecal material
- Willing to abstain from regular consumption of supplements and medications known to alter gastrointestinal function or inflammatory status during the study, until collection of faecal material
Exclusion Criteria12
- Diagnosis of type 1 and/or type 2 diabetes
- Diagnosed inflammatory bowel disease (IBD)
- Current diagnosis of psychiatric disease/s or syndromes
- Current diagnosis of neurodegenerative disease
- Current pregnancy or breastfeeding
- History of complicated gastrointestinal surgery
- Systemic use of antibiotics and/or steroid medication in the last 4 months prior to inclusion
- Regular use of any non-steroidal anti-inflammatory drug (NSAID) for the last 2 months
- Consumption of any NSAID within 3 days of sample collection
- Current (or within the last 4 weeks prior to study start) use of probiotic supplementation
- Any condition or intake of medication which could substantially interfere with the outcome of the study, as decided by the principal investigator's discretion
- After being included in the study and until collection of faecal material, starting any medication or treatment that could potentially influence the study participation and/or study analysis
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06981663
Related Trials
Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients
NCT071167468 locations
Prospective Exploratory Study on the Comprehensive Application Effectiveness of Exercise Prescription Decision Support Tools in the Management of Patients With "Four Highs" (Hypertension, Hyperglycemia, Hyperlipidemia, Hyperuricemia)
NCT074005491 location
A Dose Escalation Study of IG3018 in Subjects With Hyperuricemia With or Without Chronic Kidney Disease
NCT063109676 locations
A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia
NCT068590732 locations
This Study is to Estimate the Efficacy of Hemodialysis Alone for Uric Acid Clearance in Patients on Hemodialysis. In Order to Evaluate the Need of Adjuvant Uric Acid Lowering Therapy
NCT071443321 location